ML-T7
Based on 1 Customer Validation
ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1. ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.93%
- CAS 番号: 459789-75-4
- 分子式: C27H17Cl2NO5
- 分子量:506.33
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
ML-T7(10 μM, 0-6 days) enhances TCR/STAT5 signaling and promotes CD8+ cell antitumor activity through Tim-3[1].
ML-T7(10 μM, 24 h) promotes DC maturation and function through Tim-3 and Tim-4, enhances DC antigen-presenting ability[1].
ML-T7(10 μM, 24 h) enhances CTL activation and cytokine production, decreases apoptosis of CTLs[1].
ML-T7(10 μM, 48 h) significantly enhances the production of IFN-γ, TNF-α, CD107a, and granzyme B in human NK cell line NK92 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CD8+ cell
-
Concentration:10 μM
-
Incubation Time:0-6 days
-
Result:Increased the phosphorylation of phospholipase C–γ1(PLC-γ1), ZAP70, LCK, ERK1/2, and STAT5 upon anti-CD3/CD28 stimulation.
-
Cell Line:Bone Marrow Cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Increased the expression of DC maturation markers.
ML-T7 (20 mg/kg; Intraperitoneal injection; every 2 days, 10 times) synergizes with Nivolumab (HY-P9903A) to improve the antitumor efficacy of Nivolumab (HY-P9903A) antibodies, and effectively improves HCC mice survival[1].
ML-T7 (50 mg/kg, Intraperitoneal injection; every 2 days for 3 weeks)shows a good safety profile in mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:10-week-old mice with spontaneous orthotopic HCC[1]
-
Dosage:10-50 mg/kg
-
Administration:Intraperitoneal injection (i.p.), every 2 days, 10 times
-
Result:Increased CD8+ T cells in both tumor and spleen. Inhibited T cell exhaustion. Promoted the function of CTLs, NK cells, and DCs.
-
Animal Model:10-week-old mice with orthotopic Akt/c-Myc HCC[1]
-
Dosage:20 mg/kg
-
Administration:Intraperitoneal injection (i.p.), every 2 days, 10 times
-
Result:Indicated stronger antituomr activity when treated with ML-T7 and Nivolumab (HY-P9903A). Rejuvenated NK cells by the combination therapy. Inhibited the accumulation of MDSCs and Tregs.
化学情報
-
CAS 番号 459789-75-4
-
性状 Solid
-
分子量 506.33
-
分子式 C27H17Cl2NO5
-
Color White to yellow
-
SMILES
O=C1C2=C(C(C13OC(C4C(N(C5=CC=C(C=C5Cl)Cl)C(C43)=O)=O)C6=CC=C(C)C=C6)=O)C=CC=C2
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
DMSO : 66.67 mg/mL (131.67 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (285 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9750 mL | 9.8750 mL | 19.7500 mL | 49.3749 mL |
| 5 mM | 0.3950 mL | 1.9750 mL | 3.9500 mL | 9.8750 mL | |
| 10 mM | 0.1975 mL | 0.9875 mL | 1.9750 mL | 4.9375 mL | |
| 15 mM | 0.1317 mL | 0.6583 mL | 1.3167 mL | 3.2917 mL | |
| 20 mM | 0.0987 mL | 0.4937 mL | 0.9875 mL | 2.4687 mL | |
| 25 mM | 0.0790 mL | 0.3950 mL | 0.7900 mL | 1.9750 mL | |
| 30 mM | 0.0658 mL | 0.3292 mL | 0.6583 mL | 1.6458 mL | |
| 40 mM | 0.0494 mL | 0.2469 mL | 0.4937 mL | 1.2344 mL | |
| 50 mM | 0.0395 mL | 0.1975 mL | 0.3950 mL | 0.9875 mL | |
| 60 mM | 0.0329 mL | 0.1646 mL | 0.3292 mL | 0.8229 mL | |
| 80 mM | 0.0247 mL | 0.1234 mL | 0.2469 mL | 0.6172 mL | |
| 100 mM | 0.0197 mL | 0.0987 mL | 0.1975 mL | 0.4937 mL |
ML-T7 関連分類
HY-163028 関連分類
Powered by Bioz